Press-release for stocks for jnj

for symbols : Jnj

save search

Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $30.49 1.84% 350K

Health Technology

| 0.0% | O: -0.13% H: 0.0% C: 0.0%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| 0.0% | O: 0.79% H: 0.0% C: 0.0%
ABT | News | $106.76 1.42% 3.8M

Health Technology

| 0.0% | O: -0.75% H: 0.0% C: 0.0%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| 0.0% | O: 0.82% H: 0.0% C: 0.0%
first treatment for

FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
Published: 2024-04-19 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| 0.0% | O: 0.79% H: 0.0% C: 0.0%
fda for car-t

Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
Published: 2024-04-18 (Crawled : 14:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| 0.12% | O: 0.12% H: 0.0% C: 0.0%
fda biosimilar approval for stelara

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
GNMSF | $290.38 220

Health Technology

| -0.35% | O: 4.94% H: 0.0% C: -3.66%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -2.16% | O: -2.09% H: 0.0% C: 0.0%
GMAB | $28.805 1.68% 80K

Health Technology

| -3.09% | O: -1.29% H: 1.91% C: 1.27%
darzalex sales first for

Robbins Geller Rudman & Dowd LLP, Lieff Cabraser Heimann & Bernstein LLP, and Dugan Law Firm, APLC Announce a $78 Million Class Action Settlement for Third Party Payors That Paid or Reimbursed Costs for Prescription Opioids or Treatment Related to Opioid Misuse, Addiction, and/or Overdose
Published: 2024-04-15 (Crawled : 20:00) - prnewswire.com
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -2.16% | O: -2.09% H: 0.0% C: 0.0%
opioid million treatment for

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-15 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -2.2% | O: -0.04% H: 0.0% C: 0.0%
avb-101 first dementia for trial

AstraZeneca Wins Label Expansion for Severe Asthma Drug in Younger Kids
Published: 2024-04-12 (Crawled : 14:30) - biospace.com/
PRGO | $30.49 1.84% 350K

Health Technology

| -3.96% | O: -0.13% H: 0.0% C: -2.94%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -3.82% | O: -1.65% H: 0.0% C: 0.0%
ABT | News | $106.76 1.42% 3.8M

Health Technology

| -4.53% | O: -1.06% H: 0.21% C: -1.05%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -4.0% | O: -3.02% H: 0.0% C: 0.0%
drug label astrazeneca expansion for kids

Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
Published: 2024-04-12 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -3.82% | O: -1.65% H: 0.0% C: 0.0%
expected year revenue for financial

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | $1.68 0.6% 110K

| 3.64% | O: -3.03% H: 4.38% C: 1.87%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -4.23% | O: 0.21% H: 0.0% C: 0.0%
risk solutions for collaboration

Busy Weekend Sees Tumor-Agnostic Win for Enhertu, Another Rejection for Supernus
Published: 2024-04-08 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 600K

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
PRGO | $30.49 1.84% 350K

Health Technology

| -4.33% | O: 0.96% H: 1.17% C: 0.16%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -4.97% | O: -0.48% H: 0.0% C: 0.0%
ABT | News | $106.76 1.42% 3.8M

Health Technology

| -4.32% | O: 0.09% H: 0.16% C: -0.7%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -3.02% | O: 0.84% H: 0.0% C: 0.0%
for

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
Published: 2024-04-06 (Crawled : 16:20) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| Email alert Add to watchlist
fda treatment for car-t

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| Email alert Add to watchlist
carvykti fda first approved one treatment for therapy

FDA Greenlights New Antibiotic for SAB, Pneumonia
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 600K

Health Technology

| -3.54% | O: -1.77% H: 0.0% C: -1.81%
PRGO | $30.49 1.84% 350K

Health Technology

| -4.48% | O: -0.22% H: 0.8% C: 0.06%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -6.72% | O: -1.84% H: 0.0% C: 0.0%
ABT | News | $106.76 1.42% 3.8M

Health Technology

| -3.37% | O: -0.37% H: 1.42% C: 1.37%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -6.35% | O: -3.44% H: 0.0% C: 0.0%
fda for

Basilea Wins FDA Approval for Antibiotic Ending 15-Year Regulatory Quest
Published: 2024-04-04 (Crawled : 15:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.12% | O: -1.51% H: 0.0% C: 0.0%
fda approval

HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.12% | O: -1.51% H: 0.0% C: 0.0%
publication care

FDA Approves Vanda Schizophrenia Drug for Bipolar I Disorder
Published: 2024-04-03 (Crawled : 13:30) - biospace.com/
PRGO | $30.49 1.84% 350K

Health Technology

| -4.09% | O: -0.29% H: 1.34% C: -0.64%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.1% | O: 0.02% H: 0.0% C: 0.0%
ABT | News | $106.76 1.42% 3.8M

Health Technology

| -5.02% | O: 0.11% H: 0.37% C: -0.77%
SNY | News | $46.545 2.55% 2.3M

Health Technology

| -4.59% | O: 0.69% H: 0.0% C: 0.0%
fda drug schizophrenia

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
NBTX | $5.69 3.45% 1.2K

Manufacturing

| -9.84% | O: 3.11% H: 1.19% C: -2.54%
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.1% | O: 0.02% H: 0.0% C: 0.0%
lung cancer treatment

Teva, Viatris Again Challenge J&J Patent for Schizophrenia Drug with Appeals ...
Published: 2024-04-02 (Crawled : 13:00) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.13% | O: -0.77% H: 0.8% C: 0.74%
drug patent schizophrenia

Teva, Viatris Again Challenge J&J Patent for Schizophrenia Drug with Appeals Court Win
Published: 2024-04-02 (Crawled : 12:30) - biospace.com/
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| -8.13% | O: -0.77% H: 0.8% C: 0.74%
drug patent schizophrenia

FDA Approves Treatments for Anemia in Chronic Kidney Disease, Hepatitis
Published: 2024-03-29 (Crawled : 19:00) - biospace.com/
SNY | News | $46.545 2.55% 2.3M

Health Technology

| Email alert Add to watchlist
ABT | News | $106.76 1.42% 3.8M

Health Technology

| Email alert Add to watchlist
JNJ | News | $147.17 0.98% 3.2M

Health Technology

| Email alert Add to watchlist
PRGO | $30.49 1.84% 350K

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 600K

Health Technology